Summer, coronavirus and dry eye syndrome – effective treatments Letter to the Editor

Article Sidebar

PDF (Język Polski)


Published: Jun 30, 2020
DOI: https://doi.org/10.24292/01.OT.300620.12
Keywords:
coronavirus, summer, dry eye syndrome

Main Article Content

Marta Misiuk-Hojło
Katedra i Klinika Okulistyki, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
http://orcid.org/0000-0002-4020-3203
Grzegorz Jasina
Szpital Specjalistyczny im. Stefana Żeromskiego w Krakowie
http://orcid.org/0000-0002-5481-8436

Abstract

Since December, the COVID-19 pandemic has been affecting many people. Today we live in a different reality. However, despite the lethal threat, we still need to help patients with various medical problems. Often people with dry eye syndrome visit the ophthalmology’ consulting room. It’s usually not a serious complication, but it can severely hinder patients' lives and, in exceptional cases, ruin their vision. The article will present the symptoms of dry eye syndrome, causes and effective treatments. There are also discussed: the problem of COVID-19 as a disease entity, ocular symptoms whom may cause and the incidence of eye symptoms among people with this disease. In addition it will be described the connection between coronavirus and dry eye syndrome.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Misiuk-Hojło M, Jasina G. Summer, coronavirus and dry eye syndrome – effective treatments. Ophthatherapy [Internet]. 2020Jun.30 [cited 2024Dec.22];7(2):168-72. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1050
Issue
Vol 7 No 2 (2020)
Section
Covid – special report
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Farrand KF, Fridman M, Stillman IÖ et al. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol. 2017; 182: 90-8.
2. Ambroziak AM. Ciężki zespół suchego oka – epidemiologia i klasyfikacja na podstawie aktualnych wytycznych Oddisey Algorytm. Okulistyka. 2014; 25(1).
3. Satitpitakul V, Kheirkhah A, Crnej A et al. Determinants of Ocular Pain Severity in Patients With Dry Eye Disease. Am J Ophthalmol. 2017; 179: 198-204.
4. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 2004; 23(8): 762-70.
5. Bhargava R, Kumar P. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea. 2015; 34: 413-20.
6. Dry Eye Assessment and Management Study Research Group, Asbell PA, Maguire MG et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med. 2018; 378: 1681-90.
7. Fryczkowski P. Leczenie zespołu suchego oka za pomocą kwantowego rezonansu komórkowego. OphthaTherapy. 2020; 1: 66-9.
8. Jones L, Downie LE, Korb D et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017; 15(3): 575-628.
9. de Paiva CS, Pflugfelder SC, Ng SM et al. Topical cyclosporine a therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019; 9(9): CD010051. https://doi.org/10.1002/14651858.CD010051.pub2.
10. Malta JB, Soong HK, Shtein RM et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea. 2010; 29(12): 1392-96.
11. Avunduk AM, Avunduk MC, Varnell ED et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003; 136(4): 593-602.
12. Pinto-Fraga J, López-Miguel A, González-García MJ et al. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial. Ophthalmology. 2016; 123(1): 141-53.
13. Drouault-Holowacz S, Bieuvelet S, Burckel A et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol. 2009; 19(3): 337-42.
14. Shigeyasu C, Hirano S, Akune Y et al. Diquafosol Tetrasodium Increases the Concentration of Mucin-like Substances in Tears of Healthy Human Subjects. Curr Eye Res. 2015; 40(9): 878-83.
15. Ueda K, Matsumiya W, Otsuka K et al. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol. 2015; 15: 58.
16. Prost ME. Koronawirus a narząd wzroku. Możliwości zakażenia, objawy kliniczne i profilaktyka w gabinecie okulistycznym. OphthaTherapy. 2020; 25(1): 5-9.
17. Chen L, Liu M, Zhang Z et al. Ocular manifestation of a hospitalized patient with confirmed 2019 novel coronavirus disease. BJ Ophthalmol. 2020; 104(6): 748-51.
18. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm. 2020: 1-5. https://doi.org/10.1080/09273948.2020.1738501.
19. Hu K, Patel J, Patel BC. Ophthalmic Manifestation of Coronavirus (COVID-19). StatPearls Publishing 2020.
20. Sun X, Zhang X, Chen X et al. The infection evidence of SARS-COV-2 in ocular surface: single-center cross-sectional study. medRxiv 2020. https://doi.org/10.1101/2020.02.26.20027938.
21. Wu P, Duan F, Luo C et al. Characteristics of Ocular Findings of Patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020; 138(5): 575-8.
22. Jacomy H, Talbot PJ. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology. 2003; 315(1): 20-33.
23. Yeh EA, Collins A, Cohen ME et al. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics. 2004; 113(1): e73-e76. https://doi.org/10.1542/peds.113.1.e73.